Figure 1.

Immune checkpoint ligands CD80 and CD86 are expressed in most tumor biopsies derived from DLBCL patients after receiving CAR (2^nd Gen) T cells

(A) Evaluation of CD80/86 expression in lymphoma slides before and after treatment or at relapse as a mean H score, separated into tumor and tumor microenvironment cells where possible. See also Figures S1A‒S1C. Bar plots represent mean ± SEM of five high-power fields per slide. Statistical significance levels were determined by using a non-adjusted t test and reported according to p values (thresholds below).

(B) Representative optical field section of DLBCL patient lymph node slides stained to show CD80/CD86 expression before and after treatment with tisagenlecleucel. Scale bars, 100 μm (original) and 20 μm (zoomed images).

(C) Antigen expression of CD80 and CD86 in singularized DLBCL biopsy samples (CD19⁺/CD5^– gated) and peripheral blood samples of CLL (CD19⁺/CD5⁺ gated) and healthy donors (CD19⁺/CD20⁺ gated) measured by flow cytometry and plotted in comparison. Bar plots represent mean fluorescence intensity of each sample.

(D) Comparison of CD80/CD86 transcript abundance across different cell types and lymphoma entities in the Brune et al. set.³² The horizontal line marks the median abundance of CD80/86 in healthy germinal center B cells.

(E) CD86 transcriptional abundance across COO classification, upper plot from the Schmitz et al. set³³ and lower plot from the Chapuy et al. set.³⁴

(F and G) CD80/CD86 transcriptional abundance across genetic subtype clusters in the Chapuy et al. set and across revised LymphGen subtypes in the Schmitz et al. set. Horizontal line marks median abundance of all subtypes, which also serves as the reference group for individual group statistical testing.

Statistical significance in transcriptomic data was evaluated using a one-sided unpaired non-adjusted Mann-Whitney U test and significance levels reported according to p values: ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.